Determination of whether the biological variation of fasting lipids differs between simvastatin and atorvastatin therapy in patients with type 2 diabetes: implications for treating to target

Submission date	Recruitment status	Prospectively registered
16/08/2007	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
03/09/2007	Completed	[X] Results
Last Edited	Condition category	[] Individual participant data
10/05/2011	Nutritional, Metabolic, Endocrine	

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Stephen Atkin

Contact details

Michael White Diabetes Centre Hull Royal Infirmary 220-236 Analby Road Hull United Kingdom HU3 2JZ

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Hull and East Yorkshire Hospital NHS Trust, Research and Development Department - R0066

Study information

Scientific Title

Acronym

SAT - Simvastatin and Atorvastatin Therapy

Study objectives

The biological variability for lipids is less after atorvastatin therapy compared to simvastatin. Therefore, to consistently achieve a target cholesterol of 5.0 mmol/L the levels will have to be reudced further with simvastatin than with atorvastatin, in orderto account for the increased variability of cholesterol found with the former.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South Humber Local Research Ethics Commitee (ref: 04/Q1105/40)

Study design

Non-randomised controlled cross-over study.

Primary study design

Interventional

Secondary study design

Non randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Type 2 diabetes, hypercholestrolemia

Interventions

All participants were on stable doses of medications (i.e. either atorvastatin 10 mg or simvastatin 40 mg) for at least 3 months. Biological variations of Total Cholesterol (TC), High-Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), triglycerides, high sensitivity C-reactive protein (hsCRP), Vitamin D levels and oxidative stress markers were assessed by measuring 12-hour fasting blood samples at four-day intervals on 10 consecutive occasions. Thereafter the patients on simvastatin were changed to atorvastatin 10

mg and vice versa. After 3 months, the biological variation of lipid parameters, hsCRP, Vitamin D levels and oxidative stress markers were assessed again by measuring fasting blood samples at four-day intervals on 10 consecutive occasions in these patients.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

simvastatin, atorvastatin

Primary outcome measure

Biological variability of TC and LDL-C (see Interventions for timepoints of measurement).

Secondary outcome measures

Biological variation of triglycerides and hsCRP (see Interventions for timepoints of measurement).

Overall study start date

01/02/2005

Completion date

01/02/2007

Eligibility

Key inclusion criteria

Type 2 diabetes on either atorvastatin 10 mg or simvastatin 40 mg.

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

20

Key exclusion criteria

- 1. Not on concomitant fibrate or additional lipid lowering therapy
- 2. Inadequately treated hypothyroidism
- 3. Nephrotic syndrome

Date of first enrolment

01/02/2005

Date of final enrolment

01/02/2007

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Michael White Diabetes Centre
Hull
United Kingdom
HU3 2JZ

Sponsor information

Organisation

Hull and East Yorkshire Hospitals NHS trust (UK)

Sponsor details

c/o Mrs Nina Dunham
Research and Development Manager
Castle Hill Hospital
Castle Road
Cottingham
East Yorkshire
Hull
England
United Kingdom
HU16 5JQ

Sponsor type

Hospital/treatment centre

Website

http://www.hey.nhs.uk/

ROR

https://ror.org/01b11x021

Funder(s)

Funder type

University/education

Funder Name

University of Hull (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2008		Yes	No